Manufacturing USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns BioSpaceAlmost half of the top 100 medicines vulnerable to supply disruptions in the U.S.ManufacturingRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. ManufacturingRead full story Post navigation Previous: Allogene stock sails after CAR T clears residual lymphoma in early data cutNext: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results Related Stories Manufacturing Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing pharminent May 7, 2026 Manufacturing Lilly inflates US facility investment spending by $4.5bn pharminent May 6, 2026 Manufacturing PCI adds US sterile fill/finish capabilities through $1B global expansion drive pharminent May 4, 2026
